

REMARKS

The above Preliminary Amendment is made to remove multiple dependencies in the claims. No new matter is added by these amendments, and they are fully supported by the specification. A version with markings to show the changes made is attached hereto. Applicants respectfully request the entry of these amendments.

Respectfully submitted,

Date: 17 July 2001


Elizabeth Selby
Attorney of Record, Reg. No. 38,298

GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-3934
Facsimile: 919-483-7988

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents Washington, D.C. 20231 on 17 July 2001


Marilyn Eldridge

Version with Markings to Show Changes Made

*RTA: RV
THERAPY AGENT*

1. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient, comprising:

- administering the RTA to a mesenchymal stem cell or pre-adipocyte cell under culture conditions appropriate for adipogenesis; and
- monitoring the cell for an inhibition of adipogenesis; (FAT FORMATION) whereby inhibition of adipogenesis indicates the RTA has the capacity to increase lipodystrophy or dyslipidemia in the patient.

2. The method of claim 1, wherein the RTA is administered to a mesenchymal stem cell.

3. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient comprising:

- administering the RTA to a cell capable of metabolizing lipids under conditions permissible for lipogenesis; and monitoring net lipogenesis in the cell, whereby a change in net lipogenesis in the cell indicates the protease inhibitor can affect lipodystrophy or dyslipidemia, thereby screening the RTA for its capacity to affect lipodystrophy or dyslipidemia in the patient.

4. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient comprising:

- administering the RTA to a cell capable of metabolizing lipids under conditions permissible for lipolysis; and *DESTRUCTION/BREAK-DOWN OF FAT*
- monitoring net(lipolysis) in the cell, whereby a change in net lipolysis in the cell indicates the protease inhibitor can affect lipodystrophy or dyslipidemia, thereby screening the RTA for its capacity to affect lipodystrophy or dyslipidemia in the patient

5. (Cancelled).

6. (Cancelled).

7. (Cancelled).

8. (Cancelled).

9. (Cancelled).

10. (Cancelled).

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient comprising:

(a) administering the RTA to a cell capable of metabolizing lipids under conditions permissible for metabolizing lipids; and

(b) monitoring the expression of a PPAR γ :RXR-regulated gene in the cell, whereby a change in gene expression of the PPAR γ :RXR-regulated

gene indicates the RTA can affect lipodystrophy or dyslipidemia, thereby screening the RTA for its capacity to affect lipodystrophy or dyslipidemia in the patient.

27. The method of claim 26, wherein the cell capable of metabolizing lipids is selected from the group consisting of a mesenchymal stem cell, a liver cell, a muscle cell, an osteoblast, a Schwann cell, an adipocyte, and a pre-adipocyte.
28. The method of claim 26, wherein the RTA is a protease inhibitor.
29. The method of claim 26, wherein the PPAR γ :RXR-regulated gene is a gene which encodes aP2.
30. The method of claim 26, wherein the PPAR γ :RXR-regulated gene is a gene which encodes lipoprotein lipase.

PI PROTRAP 31. A method of screening a PI for its capacity to affect lipodystrophy, dyslipidemia, or retinoid-associated toxicity in a patient comprising:

- (a) administering the PI to a cell containing a retinoid-regulated gene in the presence of a retinoid; and
- (b) monitoring the cell for a change in the expression of the retinoid-activated gene, whereby a change in the expression of the retinoid-activated gene indicates the PI can affect affect lipodystrophy, dyslipidemia, or retinoid-associated toxicity, thereby screening the PI for its capacity to affect affect lipodystrophy, dyslipidemia, or retinoid-associated toxicity in the patient.

32. The method of claim 31, wherein the cell is an adipocyte or a preadipocyte.

33. The method of claim 31, wherein the PI is an HIV PI.

34. The method of claim 31, wherein the retinoid-activated gene is a gene which encodes alkaline phosphatase.

affect

35. A method of screening a compound for its potential to effect fat metabolism comprising:

(a) contacting a PPAR(receptor-ligand complex with the compound; and

(b) monitoring the complex for displacement of the receptor ligand from the complex, whereby a compound that displaces the receptor has a potential to effect fat metabolism, thereby screening the compound for its potential to effect fat metabolism.

36. A method of screening a compound for its potential to effect fat metabolism comprising:

(a) contacting a PPAR(receptor-ligand complex with the compound; and

(b) monitoring the complex for binding of the compound to the complex, whereby a compound that binds to the complex receptor has a potential to effect fat metabolism, thereby screening the compound for its potential to effect fat metabolism.

37. (Cancelled).

38. (Cancelled).

39. (Cancelled).

40. (Cancelled).

41. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient, comprising:

(a) administering the RTA to a mammal susceptible to diet-induced obesity; and

(b) monitoring the mammal for an increase in serum lipids, whereby the increase in net serum lipids indicates the RTA has the capacity to increase lipodystrophy or dyslipidemia in a patient.

42. The method of claim 41, wherein the change in serum lipids is indicated by a change in serum triglycerides, free fatty acids, glycerol, or cholesterol.

43. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient comprising:

- a) administering the RTA to a mammal susceptible to diet-induced obesity; and
- b) monitoring net fat deposition in the mammal, whereby a change in net fat deposition indicates the RTA can affect lipodystrophy or dyslipidemia, thereby screening the RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient.

44. The method of claim 43, wherein the change in net fat deposition is indicated by a change in the weight of fat pads.

45. The method of claim 43, wherein the change in net fat deposition is indicated by a change in expression or activity of proteins produced by adipocytes.

46. The method of claim 43, wherein the fat deposition results in interscapular or epididymal fat depots.

47. A method of screening an RTA for its capacity to affect lipodystrophy or dyslipidemia in a patient, comprising:

- (a) administering the RTA to a mammal susceptible to diet-induced obesity; and
- (b) monitoring the mammal for an increase in blood urea nitrogen or glucose, whereby the increase in blood urea nitrogen or glucose indicates the RTA has the capacity to affect lipodystrophy or dyslipidemia in a patient.

48. A method of screening an RTA for its capacity to affect lipodystrophy, dyslipidemia or retinoid associated toxicities in a patient, comprising:

- (a) administering the RTA to a cell containing a retinoid-regulated gene in the presence of a retinoid; and

(a)

monitoring the mammal for a change in the expression of a retinoid-activated gene, whereby a change in the expression of the retinoid-activated gene indicates the RTA can affect lipodystrophy, dyslipidemia, or retinoid associated toxicities, thereby screening the RTA for its capacity to affect lipodystrophy, dyslipidemia, or retinoid associated toxicities in a patient.

49. (Cancelled).

50. (Cancelled).

51. (Cancelled).

52. (Cancelled).

53. (Cancelled).

54. (Cancelled).

55. A transgenic mouse whose somatic cells comprise and express a transgene conferring sensitivity to an RTA, wherein the total native and transgene expressed in the transgenic mouse is higher than the native gene expressed in a non-transgenic mouse, which transgenic mouse has a phenotype of increased sensitivity to the RTA.

56. A transgenic mouse whose somatic cells comprise and overexpress ubiquitously in all tissues a transgene conferring sensitivity to an RTA, wherein the total native and transgene expressed in the transgenic mouse is higher than the native gene expressed in a non-transgenic mouse, which transgenic mouse has a phenotype of increased sensitivity to the RTA.

57. (Cancelled).

58. A method of identifying a compound for treating RTA-induced lipodystrophy or

dyslipidemia in a mammal, comprising administering the compound to an RTA-sensitive mouse, and monitoring the mouse for a change in the expression of a gene and/or the activity of a gene product associated with lipodystrophy or dyslipidemia, a change in fat distribution, and/or a change in serum lipids, whereby a change in the expression of the gene and/or the activity of the gene product, an increase in fat distribution, or a decrease in serum lipids indicates the compound has the capacity to decrease lipodystrophy or dyslipidemia in the mammal and thereby treat RTA-induced lipodystrophy or dyslipidemia in a mammal.

59. The method of claim 58, wherein the RTA is a HIV protease inhibitor, HIV NRTI or HIV NNRTI.

60. A method of detecting a capacity of a compound to cause RTA-induced lipodystrophy or dyslipidemia in a mammal, comprising administering the compound to an RTA-sensitive mouse, monitoring the mouse for a change in expression of a gene and/or the activity of a gene product associated with lipodystrophy, dyslipidemia or retinoid associated toxicities in the mouse, a change in fat distribution, and/or a change in serum lipids, whereby a change in the expression of the gene and/or the activity of the gene product, an increase in fat distribution, or a decrease in serum lipids indicates the compound has the capacity to cause RTA-induced lipodystrophy, dyslipidemia or retinoid associated toxicities in the mammal.

61. The method of claim 60, wherein the RTA is a protease inhibitor.

62. A method of classifying a patient as being susceptible to RTA-induced lipodystrophy or dyslipidemia, comprising administering RTA to the patient, monitoring the patient for a change in the expression of a gene and/or the activity of a gene associated with lipodystrophy, dyslipidemia or retinoid associated toxicities, a change in fat distribution, and/or a change in serum lipids, whereby a change in the expression of the gene and/or the activity of the gene product, an increase in fat distribution, and/or a decrease in serum lipids indicates the patient may be susceptible to lipodystrophy or dyslipidemia; thereby classifying the

patient as being susceptible to RTA-induced lipodystrophy, dyslipidemia or retinoid associated toxicities.

63. The method of claim 62, wherein the RTA is a HIV protease inhibitor, HIV NRTI, HIV, NNRTI.

64. (Cancelled).

65. (Cancelled).

66. (Cancelled).

67. (Cancelled).

68. (Cancelled).

69. (Cancelled).

70. (Cancelled).

71. (New) The method of claim 1, wherein the RTA is a protease inhibitor.

72. (New) The method of claim 1, wherein the RTA is a NRTI.

73. (New) The method of claim 1, wherein the culture conditions comprise culturing the cell in the presence of a receptor ligand selected from the group consisting of a PPAR γ ligand, a RXR ligand, a retinoic acid receptor ligand, insulin, an insulin-like growth factor, a glucocorticoid receptor ligand, and a cAMP-elevating agent.

74. (New) The method of claim 73, wherein the receptor ligand is a PPAR γ ligand.

75. (New) The method of claim 74, wherein the PPAR γ ligand is an agonist of PPAR γ .

76. (New) The method of claim 75, wherein the PPAR γ agonist is a thiazolidinedione.

77. (New) The method of claim 73 wherein the receptor ligand is a RXR ligand.

78. (New) The method of claim 77, wherein the RXR ligand is an agonist of RXR.

79. (New) The method of claim 78, wherein the RXR agonist is LGD1069, LG100268, 9-cis retinoic acid, or all-trans retinoic acid.

80. (New) The method of claim 73, wherein the receptor ligand is a retinoic acid receptor ligand.

81. (New) The method of claim 80, wherein the retinoic acid ligand is CH55, 9-cis retinoic acid, or all-trans retinoic acid.

82. (New) The method of claim 73, wherein the receptor ligand is insulin.

83. (New) The method of claim 73, wherein the receptor ligand is an insulin-like growth factor.

84. (New) The method of claim 71, wherein the protease inhibitor is an aspartyl protease inhibitor.

85. (New) The method of claim 84, wherein the aspartyl protease inhibitor is a viral aspartyl protease inhibitor.

86. (New) The method of claim 85, wherein the viral aspartyl protease inhibitor is an HIV protease inhibitor.

87. (New) The method of claim 72, wherein the NRTI is an HIV NRTI.

88. (New) The method of claim 2, wherein the mesenchymal stem cell has the characteristics of a C3H10T1/2 cell.

89. (New) The method of claim 88, wherein the mesenchymal stem cell is a mammalian primary cell.

90. (New) The method of claim 89, wherein the mammalian primary cell is a human primary cell.

91. (New) The method of claim 3, wherein the cell to which the RTA is administered is selected from the group consisting of a mesenchymal stem cell, a liver cell, a muscle cell, an osteoblast, a Schwann cell, an adipocyte, and a pre-adipocyte.

92. (New) The method of claim 3, wherein the RTA is a protease inhibitor.

93. (New) The method of claim 3, wherein the RTA is a NRTI.

94. (New) The method of claim 3, wherein the culture conditions comprise culturing the cell in the presence of a receptor ligand selected from the group consisting of a PPAR γ ligand, a RXR ligand, a retinoic acid receptor ligand, insulin, an insulin-like growth factor, a glucocorticoid receptor ligand, and a cAMP-elevating agent.

95. (New) The method of claim 94, wherein the receptor ligand is a PPAR γ ligand.

96. (New) The method of claim 95, wherein the PPAR γ ligand is an agonist of PPAR γ .

97. (New) The method of claim 96, wherein the PPAR γ agonist is a thiazolidinedione.

98. (New) The method of claim 94, wherein the receptor ligand is a RXR ligand.

99. (New) The method of claim 98, wherein the RXR ligand is an agonist of RXR.

100. (New) The method of claim 99, wherein the RXR agonist is LGD1069, LG100268, 9-cis retinoic acid, or all-trans retinoic acid.

101. (New) The method of claim 94, wherein the receptor ligand is a retinoic acid receptor ligand.

102. (New) The method of claim 101, wherein the retinoic acid ligand is CH55, 9-cis retinoic acid, or all-trans retinoic acid.

103. (New) The method of claim 94, wherein the receptor ligand is insulin.

104. (New) The method of claim 94, wherein the receptor ligand is an insulin-like growth factor.

105. (New) The method of claim 92, wherein the protease inhibitor is an aspartyl protease inhibitor.

106. (New) The method of claim 105, wherein the aspartyl protease inhibitor is a viral aspartyl protease inhibitor.

107. (New) The method of claim 106, wherein the viral aspartyl protease inhibitor is an HIV protease inhibitor.

108. (New) The method of claim 93, wherein the NRTI is an HIV NRTI.

109. (New) The method of claim 91, wherein the mesenchymal stem cell has the characteristics of a C3H10T1/2 cell.

110. (New) The method of claim 109, wherein the mesenchymal stem cell is a mammalian primary cell.

111. (New) The method of claim 110, wherein the mammalian primary cell is a human primary cell.

112. (New) The method of claim 4, wherein the cell to which the RTA is administered is selected from the group consisting of a mesenchymal stem cell, a liver cell, a muscle cell, an osteoblast, a Schwann cell, an adipocyte, and a pre-adipocyte.

113. (New) The method of claim 4, wherein the RTA is a protease inhibitor.

114. (New) The method of claim 4, wherein the RTA is a NRTI.

115. (New) The method of claim 4, wherein the culture conditions comprise culturing the cell in the presence of a receptor ligand selected from the group consisting of a PPAR γ ligand, a RXR ligand, a retinoic acid receptor ligand, insulin, an insulin-like growth factor, a glucocorticoid receptor ligand, and a cAMP-elevating agent.

116. (New) The method of claim 115, wherein the receptor ligand is a PPAR γ ligand.

117. (New) The method of claim 116, wherein the PPAR γ ligand is an agonist of PPAR γ .

118. (New) The method of claim 117, wherein the PPAR γ agonist is a thiazolidinedione.

119. (New) The method of claim 115, wherein the receptor ligand is a RXR ligand.

120. (New) The method of claim 119, wherein the RXR ligand is an agonist of RXR.

121. (New) The method of claim 120, wherein the RXR agonist is LGD1069, LG100268, 9-cis retinoic acid, or all-trans retinoic acid.

122. (New) The method of claim 115, wherein the receptor ligand is a retinoic acid receptor ligand.

123. (New) The method of claim 122, wherein the retinoic acid ligand is CH55, 9-cis retinoic acid, or all-trans retinoic acid.

124. (New) The method of claim 115, wherein the receptor ligand is insulin.

125. (New) The method of claim 115, wherein the receptor ligand is an insulin-like growth factor.

126. (New) The method of claim 113, wherein the protease inhibitor is an aspartyl protease inhibitor.

127. (New) The method of claim 126, wherein the aspartyl protease inhibitor is a viral aspartyl protease inhibitor.

128. (New) The method of claim 127, wherein the viral aspartyl protease inhibitor is an HIV protease inhibitor.

129. (New) The method of claim 114, wherein the NRTI is an HIV NRTI.

130. (New) The method of claim 112, wherein the mesenchymal stem cell has the characteristics of a C3H10T1/2 cell.

131. (New) The method of claim 130, wherein the mesenchymal stem cell is a mammalian primary cell.

132. (New) The method of claim 131, wherein the mammalian primary cell is a human primary cell.

133. (New) The method of claim 35, wherein the compound is screened for potential protease inhibitor activity.

134. (New) The method of claim 35, wherein the receptor ligand is a PPAR γ ligand.

135. (New) The method of claim 134 wherein the PPAR γ ligand is a thiazolidinedione.

136. (New) The method of claim 134, wherein the ligand is BRL49653.

137. (New) The method of claim 36, wherein the compound is screened for potential protease inhibitor activity.

138. (New) The method of claim 36, wherein the receptor ligand is a PPAR γ ligand.

139. (New) The method of claim 138, wherein the PPAR γ ligand is a thiazolidinedione.

140. (New) The method of claim 138, wherein the ligand is BRL49653.

141. (New) The method of claim 41, wherein the RTA is a protease inhibitor.

142. (New) The method of claim 41, wherein the mammal is maintained under high-fat diet conditions.

143. (New) The method of claim 41, wherein the mammal is a mouse.

144. (New) The method of claim 143, wherein the mouse has the obesity-related characteristics of a AKR/J mouse.

145. (New) The method of claim 43, wherein the RTA is a protease inhibitor.

146. (New) The method of claim 43, wherein the mammal is maintained under high-fat diet conditions.

147. (New) The method of claim 43, wherein the mammal is a mouse.

148. (New) The method of claim 147, wherein the mouse has the obesity-related characteristics of a AKR/J mouse.

149. (New) The method of claim 47, wherein the RTA is a protease inhibitor.

150. (New) The method of claim 47, wherein the mammal is maintained under high-fat diet conditions.

151. (New) The method of claim 47, wherein the mammal is a mouse.

152. (New) The method of claim 151, wherein the mouse has the obesity-related characteristics of a AKR/J mouse.

153. (New) The method of claim 48, wherein the RTA is a protease inhibitor.

154. (New) The method of claim 48, wherein the mammal is maintained under high-fat diet conditions.

155. (New) The method of claim 48, wherein the mammal is a mouse.

156. (New) The method of claim 155, wherein the mouse has the obesity-related characteristics of a AKR/J mouse.

157. (New) The method of claim 48, wherein the retinoid-activated gene is a gene which encodes alkaline phosphatase.

158. (New) The method of claim 48, wherein the retinoid-activated gene is activated by a retinoid nuclear receptor.

159. (New) The transgenic mouse of claim 55, wherein the RTA is a protease inhibitor.

160. (New) The transgenic mouse of claim 56, wherein the RTA is a protease inhibitor.

161. (New) The method of claim 58, wherein the RTA is an HIV protease inhibitor.

162. (New) The method of claim 58, wherein the gene is a retinoid-activated gene.

163. (New) The method of claim 58, wherein the gene is activated by a retinoid nuclear receptor.

164. (New) The method of claim 58, wherein the gene is a PPAR γ :RXR-activated gene.

165. (New) The method of claim 58, wherein the gene is a protease inhibitor regulated gene.

166. (New) The method of claim 58, wherein the change in gene expression comprises an increase in gene expression.

167. (New) The method of claim 58, wherein the change in gene expression comprises a decrease in gene expression.

168. (New) The method of claim 60, wherein the RTA is an HIV protease inhibitor.

169. (New) The method of claim 60, wherein the gene is a retinoid-activated gene.

170. (New) The method of claim 60, wherein the gene is activated by a retinoid

nuclear receptor.

171. (New) The method of claim 60, wherein the gene is a PPAR γ :RXR-activated gene.

172. (New) The method of claim 60, wherein the gene is a protease inhibitor regulated gene.

173. (New) The method of claim 60, wherein the change in gene expression comprises an increase in gene expression.

174. (New) The method of claim 60, wherein the change in gene expression comprises a decrease in gene expression.

175. (New) The method of claim 62, wherein the RTA is an HIV protease inhibitor.

176. (New) The method of claim 62, wherein the gene is a retinoid-activated gene.

177. (New) The method of claim 62, wherein the gene is activated by a retinoid nuclear receptor.

178. (New) The method of claim 62, wherein the gene is a PPAR γ :RXR-activated gene.

179. (New) The method of claim 62, wherein the gene is a protease inhibitor regulated gene.

180. (New) The method of claim 62, wherein the change in gene expression comprises an increase in gene expression.

181. (New) The method of claim 62, wherein the change in gene expression comprises a decrease in gene expression.